Carmustine

Generic Name: Carmustine

Brand Names: Bicnu, Gliadel, Carmustine medac (previously Carmustine Obvius)

Drug Type: Small Molecule

Chemical Formula: C_₅H_₉Cl_₂N_₃O_₂

CAS Number: 154-93-8

Unique Ingredient Identifier: U68WG3173Y

Background: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index,...

Indication: For the treatment of brain tumors, multiple myeloma, Hodgkin's disease and Non-Hodgkin's lymphomas.

Associated Conditions: Astrocytoma, Brain Stem Gliomas, Ependymoma, High Grade Glioma: Glioblastoma (GBM), Medulloblastomas, Metastatic Brain Tumors, Mycosis Fungoides (MF), Newly Diagnosed High-Grade Glioma, Recurrent Glioblastoma Multiforme (GBM), Refractory Hodgkin Lymphoma, Refractory Multiple Myeloma, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

Efaproxiral Plus Carmustine in Treating Patients With Progressive or Recurrent Malignant Glioma

Phase 1

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-21

Lead Sponsor: New Approaches to Brain Tumor Therapy Consortium

Target Recruit Count: 48

Registration Number: NCT00005855

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

and more 6 locations

Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas

Phase 3

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2003-01-27

Last Posted Date: 2013-11-06

Lead Sponsor: Colorado Health Foundation

Target Recruit Count: 270

Registration Number: NCT00003788

Locations: 🇨🇦
St. Michael's Hospital-Annex, Toronto, Ontario, Canada
🇺🇸
Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸
Rocky Mountain Neurological Associates, Englewood, Colorado, United States

and more 1 locations

Carmustine in Treating Patients With Recurrent Malignant Glioma

Phase 1

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2003-01-27

Last Posted Date: 2009-02-09

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00004028

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸
University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States

and more 6 locations

O6-benzylguanine and Carmustine in Treating Patients With Stage IA-IIA Cutaneous T-cell Lymphoma

Phase 1

Terminated

Conditions: Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma
Stage I Cutaneous T-cell Non-Hodgkin Lymphoma
Stage II Cutaneous T-cell Non-Hodgkin Lymphoma

Interventions: Drug: O6-benzylguanine
Drug: carmustine
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2013-01-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 20

Registration Number: NCT00003613

Locations: 🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States

S0001 RT and Carmustine With or Without O6BG in Patients With New Glioblastoma Multiforme or Gliosarcoma

Phase 3

Completed

Conditions: Malignant Neoplasms of Eye, Brain and Other Parts of Central Nervous System

Interventions: Drug: carmustine
Radiation: radiation therapy
Drug: O6-Benzylguanine

First Posted Date: 2003-01-27

Last Posted Date: 2013-01-30

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 183

Registration Number: NCT00017147

Locations: 🇺🇸
Freeman Cancer Institute at Freeman Health System, Joplin, Missouri, United States
🇺🇸
Great Falls Clinic, Great Falls, Montana, United States
🇺🇸
Glacier Oncology, PLLC, Kalispell, Montana, United States

and more 160 locations

Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2010-06-10

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 13

Registration Number: NCT00005981

Locations: 🇺🇸
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma

Phase 3

Completed

Conditions: Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2013-09-17

Lead Sponsor: EBMT Solid Tumors Working Party

Target Recruit Count: 460

Registration Number: NCT00005589

Locations: 🇩🇪
Universitaetsklinikum Goettingen, Goettingen, Germany
🇧🇪
Institut Jules Bordet, Brussels, Belgium
🇧🇪
U.Z. Gasthuisberg, Leuven, Belgium

and more 128 locations

Chemotherapy Followed by Radiation Therapy and Peripheral Stem Cell Transplant Compared With Chemotherapy Plus Interferon Alfa in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma

Phase 3

Conditions: Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2013-09-17

Lead Sponsor: German Low Grade Lymphoma Study Group

Registration Number: NCT00016887

Locations: 🇧🇪
AZ Sint-Jan, Brugge, Belgium
🇮🇹
Ospedale Civile Alessandria, Alessandria, Italy

Chemotherapy and Peripheral Stem Cell Transplant With or Without Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma

Phase 3

Completed

Conditions: Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2013-08-12

Lead Sponsor: Commissie Voor Klinisch Toegepast Onderzoek

Target Recruit Count: 340

Registration Number: NCT00012051

Locations: 🇳🇱
Academisch Medisch Centrum at University of Amsterdam, Amsterdam, Netherlands
🇧🇪
U.Z. Gasthuisberg, Leuven, Belgium
🇳🇱
HagaZiekenhuis - Locatie Leyenburg, 's-Gravenhage, Netherlands

and more 14 locations

SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma

Phase 3

Completed

Conditions: Lymphoma

Interventions: Biological: rituximab
Drug: CHOP regimen
Drug: cyclophosphamide
Drug: carmustine
Drug: doxorubicin hydrochloride
Drug: prednisone
Drug: vincristine sulfate
Drug: etoposide
Procedure: bone marrow ablation with stem cell support
Procedure: peripheral blood stem cell transplantation
Radiation: radiation therapy

First Posted Date: 2003-01-27

Last Posted Date: 2021-02-02

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 397

Registration Number: NCT00004031

Locations: 🇨🇦
Moncton Hospital, Moncton, New Brunswick, Canada
🇺🇸
Oregon Health & Science University, Portland, Oregon, United States
🇨🇦
Centre Hospitalier Universitaire de Quebec, Quebec City, Quebec, Canada

and more 12 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy